検索結果

0008, occurs when central retinal artery occlusion leads to irreversible impairment of visual field and vision loss. Approximately 90% of patients suffer severe visual impairment, resulting in less th...

Meetings of the Minds | Research & Development | SENJU Pharmaceutica

験 堀裕一1、和田智之2、尾松和則2 1東邦大学医学部 2千寿製薬株式会社 See more Overseas AAO 2025 開催日：2025年10月17日～2025年10月20日 開催地：Orlando, FL, USA Motugivatrep, a TRPV1 antagonist in Dry Eye Patients – Results of a Randomized, Double...

Meetings of the Minds | Research & Development | SENJU Pharmaceutica

験 堀裕一1、和田智之2、尾松和則2 1東邦大学医学部 2千寿製薬株式会社 See more Overseas AAO 2025 開催日：2025年10月17日～2025年10月20日 開催地：Orlando, FL, USA Motugivatrep, a TRPV1 antagonist in Dry Eye Patients – Results of a Randomized, Double...

elona, Spain; CEO: Jordi Martínez Rotllan; hereinafter “Brill”). Brill specializes in R&D, drug and medical device manufacturing, and sells its products primarily in Europe and the US. The Corneal...

Over-The-Counter Medicines | Business Activities | About Senju | SENJU Pharmaceutical

ical has cultivated expertise as a pioneer in over-the-counter preparations. Our OTC line of gentle and effective products includes a variety of specialized preparations formulated for different sympt...